[Coexistence strategies of invaded gobies in the Dianchi Lake, Yunnan, China]. / äº‘å—æ»‡æ± å ¥ä¾µè™¾è™Žé±¼ç±»çš„å ±å­˜ç­–ç•¥.

Gobiids are widespread invasive species, with many species from this group usually invade into the same ecosystem simultaneously. Understanding the mechanisms underlying the coexi-stence of different gobiid species in the sympatric habitats is a key issue in fish invasion ecology. Incorporating morphological analyses, spatial distribution survey, and trophic analyses, we examined the coexistence strategy of Mugilogobius myxodermus and related species (the earlier invaders) in Dianchi Lake, Yunnan, China. Our results showed significant differences in morphology and spatial distribution among the four invasive gobies species (i.e., M. myxodermus, Micropercops swinhonis, Rhinogobius giurinus and Rhinogobius cliffordpopei). The spatial niche index of M. myxodermus was the highest. Food composition between M. myxodermus and other gobies was significantly different, with the former mainly feeding on Chydorus ovalis and Cypris sp. The trophic diversity index of M. myxodermus was the highest. Overall, we found that morphological differences, spatial niche diffe-rentiation, and trophic niche differentiation contributed to the coexistence of the gobies in Dianchi Lake, which could help M. myxodermus reduce interspecific competition. Importantly, the feeding strategy is the key factor determining population size and habitas of M. myxodermus during their competition with the other gobies, and finally contributing to the dominant position in the study area.

Sex dimorphism of Yunnanilus analis and its habitat adaptation in Xingyun Lake, Yunnan, China.

Yunnanilus is a group of endemic fish inhabit in Yun-Gui Plateau and its adjacent areas. They show the characteristic of sex dimorphism, which could be an important reason for their adaptation to karst habitats. Here, we used Yunnanilus analis as the model to understand the sex dimorphism characteristics and its adaptation to the karst habitats. The sex dimorphism, female fecundity, and food specialization of Y. analis were investigated in Xingyun Lake, Jiangchuan, Yunnan. Our results showed that Y. analis exhibit sex size dimorphism (sex dimorphism index=0.23; female with larger body size). There were stains on the transverse sections at females body, but not in males. Males had dark longitudinal lines at their body sides. Morphological differences between males and females were confirmed by the results of one-way analyses of variance (ANOVA), multivariate statistical analyses, principal component analyses, discriminant analyses, and one-way analyses of similarity (ANOSIM) on total length, standard body length, fork length, head width vs. heal length, and the distance between the starting point of ventral fin to the starting point of pectoral fin vs. standard body length. Fecundity of female fish was 1364.5±489.3 (470-2430) eggs, which were positively correlated with their body size. Both female and male Y. analis mainly feed on Chironomid larvae and mayfly naiads. Their food composition was somehow similar, with significantly statistical difference. In conclusion, fecundity selection pressure and food specialization should be the main factors contributing to the evolution of Y. analis' sex dimorphism. More importantly, sex dimorphism of Y. analis is a significant adaptation to the karstic habitats.

[Ecomorphological traits explaining the competition exclusion between Oryzias and mosqui-tofish].

The theory of ecomorphology predicts that species with similar morphological traits can occupy similar ecological niche, which may cause competitive exclusion. To apply this theory into fish invasion ecology research is of significance for understanding the interaction between native and invasive species. Here, we compared the morphological difference between two native (Oryzias pectoralis, Oryzias curvinotus) and one invasive species (Gambusia affinis) to explore the competitive exclusion among them. The results showed that despite O. pectoralis and O. curvinotus were sympa-tric species, they varied in spatial distribution. Such a result supported the theory of ecomorphology, which predicts that two species with similar morphological traits might have strong competition. Moreover, their population density exhibited a significant negative relationship with that of G. affinis. The morphology of G. affinis and both Oryzias species were more similar when comparing to other fish in the assemblage. Results from the cluster analysis showed that G. affinis and Oryzias species were close in a branch, with extremely low spatial niche overlap between invasive mosquitofish and native Oryzias species. There was significant negative correlation between the population abundance of mosquitofish and Oryzias species. All the results suggested that mosquitofish led to population decline of both Oryzias species, due to the ecomorphological similarity. More studies are needed to better understand the mechanisms of G. affinis invasion in habitats of native Oryzias species.

Budesonide, but not dexamethasone, blunted the response of aldosterone to renin elevation by suppressing angiotensin converting enzyme upon high-altitude exposure.

INTRODUCTION: Inhaled budesonide is a novel approach to prevent acute mountain sickness (AMS). However, its mechanism is not completely understood. We aimed to investigate the effects of budesonide and dexamethasone on renin-angiotensin-aldosterone system in AMS prevention. MATERIALS AND METHODS: Data were obtained from a randomised controlled trial including 138 participants. The participants were randomly assigned to receive budesonide, dexamethasone or placebo as prophylaxis before they travelled to 3450 m altitude from 400 m by car. Their plasma concentrations of renin, angiotensin-converting enzyme (ACE) and aldosterone were measured at both altitudes. RESULTS: All parameters were comparable among the three groups at 400 m. After high-altitude exposure of 3450, renin in all groups increased significantly; the ACE, aldosterone concentrations, as well as the aldosterone/renin ratio, rose markedly in the dexamethasone and placebo groups but not in the budesonide group. Moreover, the aldosterone/renin ratio correlated closely with ACE concentration. CONCLUSIONS: Upon acute high-altitude exposure, budesonide, but not dexamethasone, blunted the response of aldosterone to renin elevation by suppressing angiotensin converting enzyme.

A specific objective supplemental factor in evaluating acute mountain sickness: ΔHR in combination with SaO2.

BACKGROUND: So far, there have been no measurements confirmed useful in diagnosing acute mountain sickness (AMS). The aim of this study was to determine the role of heart rate (HR) difference (ΔHR) and oxygen saturation ( SaO2) as objective risk factors in aiding the diagnosis of AMS. METHODS: A total of 1,019 participants were assigned to either the acute exposure group (AEG): from 500 m to 3,700 m by flight within 2.5 h (n = 752); or the pre-acclimatization group (PAG): ascended to 4,400 m from 3,650 m within three hours by car after adapting 33 days at 3,650 m (n = 267). The questionnaires or measurements of resting SaO2 (oxygen saturation) and HR were completed between 18 and 24 h before departure and after arrival. RESULTS: Incidence of AMS was 61.3 % (461) in AEG, with 46.1 % (347) mild cases and 15.2 % (114) severe cases. In PAG, the incidence was 38.9 % (104), with 30.7 % (82) mild cases and 8.2 % (22) severe cases. The AMS subjects showed a significant increase in HR and a decrease in SaO2 levels compared with the non-AMS subjects in both groups. ΔHR and post-exposure SaO2 were significantly correlated with the Lake Louise Score (LLS) in both groups. Stepwise logistic regression analysis revealed the ΔHR >25 and SaO2 < 88 % in AEG as well as ΔHR >15 and SaO2 < 86 % in PAG to be independent risk factors of AMS. Combining these two measurements could specifically indicate participants with AMS, which showed a positive predictive value of 89 % and specificity of 97 % in AEG as well as 85 % and 98 % in PAG. CONCLUSION: ΔHR or SaO2, as objective measurements, correlate with AMS. Combination of these two measurements may be useful as an additional specific and objective factor to further confirm the diagnosis of AMS.

Inhaled budesonide prevents acute mountain sickness in young Chinese men.

BACKGROUND: Oral glucocorticoids can prevent acute mountain sickness (AMS). Whether inhaled budesonide (BUD) can prevent AMS remains unknown. OBJECTIVE: Our aim was to investigate the effectiveness of BUD in AMS prevention. METHODS: Eighty subjects were randomly assigned to receive budesonide (BUD, inhaled), procaterol tablet (PT), budesonide/formoterol (BUD/FM, inhaled), or placebo tablet (n = 20 in each group). Subjects were treated for 3 days before ascending from 500 m to 3700 m within 2.5 h by air. Lake Louis AMS questionnaire, blood pressure, heart rate, and oxygen saturation (SpO2) were examined at 20, 72, and 120 h after high-altitude exposure. Pulmonary function was measured at 20 h after exposure. RESULTS: Compared with placebo, BUD significantly reduced the incidence of AMS (70% vs. 25% at 20 h, p < 0.05; both 10% vs. 5% at 72 and 120 h, both p > 0.05) without side effects. The relative risk was 0.357, and the risk difference was 0.45. Mean SpO2 was higher in BUD, BUD/FM, and PT groups than in the placebo group at 20 h (p < 0.05). SpO2 in all 80 subjects dropped after ascent (98.1% to 88.12%, p < 0.01) and increased gradually, but it was still lower at 120 h than at baseline (92.04% vs. 98.1%, p < 0.01). Pulmonary function did not differ among the four groups at 20 h. CONCLUSION: BUD can prevent AMS without side effects. The alleviation of AMS may be related to increased blood oxygen levels rather than pulmonary function.

Inhaled budesonide and oral dexamethasone prevent acute mountain sickness.

BACKGROUND: This double-blind, randomized controlled trial aimed to investigate inhaled budesonide and oral dexamethasone compared with placebo for their prophylactic efficacy against acute mountain sickness after acute high-altitude exposure. METHODS: There were 138 healthy young male lowland residents recruited and randomly assigned to receive inhaled budesonide (200 µg, twice a day [bid]), oral dexamethasone (4 mg, bid), or placebo (46 in each group). They traveled to 3900 m altitude from 400 m by car. Medication started 1 day before high-altitude exposure and continued until the third day of exposure. Primary outcome measure was the incidence of acute mountain sickness after exposure. RESULTS: One hundred twenty-four subjects completed the study (42, 39, and 43 in the budesonide, dexamethasone, and placebo groups, respectively). Demographic characteristics were comparable among the 3 groups. After high-altitude exposure, significantly fewer participants in the budesonide (23.81%) and dexamethasone (30.77%) groups developed acute mountain sickness compared with participants receiving placebo (60.46%) (P = .0006 and P = .0071, respectively). Both the budesonide and dexamethasone groups had lower heart rate and higher pulse oxygen saturation (SpO2) than the placebo group at altitude. Only the budesonide group demonstrated less deterioration in forced vital capacity and sleep quality than the placebo group. Four subjects in the dexamethasone group reported adverse reactions. CONCLUSIONS: Both inhaled budesonide (200 µg, bid) and oral dexamethasone (4 mg, bid) were effective for the prevention of acute mountain sickness, especially its severe form, compared with placebo. Budesonide caused fewer adverse reactions than dexamethasone.

Risk factors for high-altitude headache upon acute high-altitude exposure at 3700 m in young Chinese men: a cohort study.

BACKGROUND: This prospective and observational study aimed to identify demographic, physiological and psychological risk factors associated with high-altitude headache (HAH) upon acute high-altitude exposure. METHODS: Eight hundred fifty subjects ascended by plane to 3700 m above Chengdu (500 m) over a period of two hours. Structured Case Report Form (CRF) questionnaires were used to record demographic information, physiological examinations, psychological scale, and symptoms including headache and insomnia a week before ascending and within 24 hours after arrival at 3700 m. Binary logistic regression models were used to analyze the risk factors for HAH. RESULTS: The incidence of HAH was 73.3%. Age (p =0.011), physical labor intensity (PLI) (p =0.044), primary headache history (p <0.001), insomnia (p <0.001), arterial oxygen saturation (SaO2) (p =0.001), heart rate (HR) (p =0.002), the Self-Rating Anxiety Scale (SAS) (p <0.001), and the Epworth Sleepiness Scale (ESS) (p <0.001) were significantly different between HAH and non-HAH groups. Logistic regression models identified primary headache history, insomnia, low SaO2, high HR and SAS as independent risk factors for HAH. CONCLUSIONS: Insomnia, primary headache history, low SaO2, high HR, and high SAS score are the risk factors for HAH. Our findings will provide novel avenues for the study, prevention and treatment of HAH.

Anxiety correlates with somatic symptoms and sleep status at high altitudes.

High altitude exposure results in many physical and psychological discomforts, with anxiety and sleep disturbances being the most common ones. This cross-sectional study was performed to explore the relationship between anxiety, somatic symptoms, and sleep status at high altitude. A sample of 426 young males between 18 and 24 years old ascended from low-level land to 3600 m, where they acclimated for 40 days, before ascending to 4400 m. Questionnaires including the Louise Lake Score (LLS, for diagnosis of acute mountain sickness [AMS]), the Self-rating Anxiety Scale (SAS), the Epworth Sleepiness Scale (ESS), and the Athens Insomnia Scale (AIS) were administered immediately before departure from 3600 m (40th day) and the day after arrival at 4400 m (20 days after the first data collection). Physiological parameters were also measured. We observed that 49 of 426 and 51 of 329 people were diagnosed with anxiety according to SAS at 3600 and 4400 m, respectively. Physical symptoms were more severe in subjects with anxiety, and the severity of anxiety was significantly positively correlated to the severity of insomnia and increased heart rate (HR). Overall, these data indicate that after 40 days acclimatization in 3600 m, anxious persons have more severe somatic symptoms. When ascending to higher altitudes, these individuals are more likely to develop AMS, show more severe symptoms, and are prone to insomnia and more serious daytime sleepiness. Insomnia and elevated HR are indicators of anxiety severity.

Aurora A, Aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer.

BACKGROUND: Analysis of biopsies from a recent clinical trial suggested that Depsipeptide FK228 (DP) inhibits Aurora kinase expression in lung cancer cells. The present study was undertaken to confirm and extend these observations. RESULTS: Aurora A and B mRNA levels in lung cancer cells were considerably higher than levels in normal pulmonary epithelia. DP, TSA and SAHA inhibited Aurora A, Aurora B and survivin expression with kinetics that were remarkably similar within individual cell lines, and appeared to coincide with p53 expression status. These effects were not observed following treatment with geldanamycins. Inhibition of Aurora B transcription coincided with decreased H3K9Ac and H3K4Me2 activation marks, and accumulation of H3K9Me3, as well as MBD1, MBD2 and MBD3 repression marks within the minimal Aurora B promoter. Knockdown of MBD1, -2 or -3 did not reproducibly abrogate inhibition of Aurora or survivin expression by DP or TSA. DP and TSA decreased expression and altered localization of Aurora kinases and survivin, resulting in mitotic catastrophe in lung cancer cells. METHODS: Aurora A, and Aurora B levels in lung cancer cells and normal respiratory epithelia were assessed using quantitative RT-PCR techniques. These methods, as well as as Western blots were used to examine expression of Auroras A/B, and several related genes/proteins in lung cancer cells exposed to DP, TSA, SAHA and geldanamycins. Transient transfection promoter-reporter assays, and chromatin immunoprecipitation (ChIP) techniques were used to examine DP-mediated changes in activity and chromatin structure of the Aurora B promoter. Confocal imaging techniques were used to examine the effects of DP and TSA on mitotic progression in lung cancer cells. CONCLUSIONS: Novel transcriptional regulatory mechanisms involving Aurora kinase and survivin appear to contribute to cytotoxicity mediated by HDAC inhibitors in lung cancer cells.

[Overexpression of CHIP in chronic myeloid leukemia K562 cells induces mitotic abnormality].

This study was aimed to investigate the possible influence of a novel E3 ubiquitin ligase CHIP (carboxyl terminus of Hsc70/Hsp70-interacting protein) on biological characteristics of cancer cells. Stable overexpression models in CML K562 cells were established via lipofectamine-mediated wild type CHIP and its TPR or U-box deletion mutants gene transfection. Followed G418 pressure selection, K562-CHIP stable transfected cell clones were obtained by limited dilution. The proliferation status and cell cycle were observed by MTT assay and FACS. The expression of related proteins and morphological changes were detected by Western blot and Wright-Giemsa staining. The results showed that overexpression of wild type CHIP did not inhibit cell proliferation, but slightly increased cell ratio of G(2)/M phase. CHIP gene had no effect on the stability of BCR-ABL kinase protein. HDAC inhibitor FK228-induced BCR-ABL degradation did not enhanced by CHIP. Notably the enlarged cells and abnormal mitotic cells remarkably increased in K562 WT-CHIP cells, indicating that CHIP may involve in the regulation of mitotic process. It is concluded that wild type CHIP induces mitotic abnormity in K562 cells.